{"title":"免疫细胞三元组对衰竭的 CD8+ T 细胞进行重编程，从而有效消除肿瘤","authors":"Veronica Lise, Ines Malenica, Rahul Roychoudhuri, Enrico Lugli","doi":"10.1016/j.ccell.2024.06.010","DOIUrl":null,"url":null,"abstract":"<p>In this issue of <em>Cancer Cell</em>, Espinosa-Carrasco <em>et al</em>. show that the efficacy of cancer immunotherapies depends upon the formation of intratumoral immune triads between antigen-presenting cells and antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. This interaction reprograms tumor-specific CD8<sup>+</sup> T cells to exert potent effector functions and eradicate established solid tumors.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"366 1","pages":""},"PeriodicalIF":48.8000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immune cell triads reprogram exhausted CD8+ T cells for effective tumor elimination\",\"authors\":\"Veronica Lise, Ines Malenica, Rahul Roychoudhuri, Enrico Lugli\",\"doi\":\"10.1016/j.ccell.2024.06.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In this issue of <em>Cancer Cell</em>, Espinosa-Carrasco <em>et al</em>. show that the efficacy of cancer immunotherapies depends upon the formation of intratumoral immune triads between antigen-presenting cells and antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. This interaction reprograms tumor-specific CD8<sup>+</sup> T cells to exert potent effector functions and eradicate established solid tumors.</p>\",\"PeriodicalId\":9670,\"journal\":{\"name\":\"Cancer Cell\",\"volume\":\"366 1\",\"pages\":\"\"},\"PeriodicalIF\":48.8000,\"publicationDate\":\"2024-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ccell.2024.06.010\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2024.06.010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
在本期《癌细胞》（Cancer Cell）杂志上，Espinosa-Carrasco 等人的研究表明，癌症免疫疗法的疗效取决于抗原递呈细胞与抗原特异性 CD4+ 和 CD8+ T 细胞之间形成的瘤内免疫三联体。这种相互作用使肿瘤特异性 CD8+ T 细胞重新编程，从而发挥强大的效应功能，根除已形成的实体瘤。
Immune cell triads reprogram exhausted CD8+ T cells for effective tumor elimination
In this issue of Cancer Cell, Espinosa-Carrasco et al. show that the efficacy of cancer immunotherapies depends upon the formation of intratumoral immune triads between antigen-presenting cells and antigen-specific CD4+ and CD8+ T cells. This interaction reprograms tumor-specific CD8+ T cells to exert potent effector functions and eradicate established solid tumors.
期刊介绍：
Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows:
Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers.
Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice.
Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers.
Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies.
Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
